Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• Lung Transplantation: Criteria and Long-Term Outcomes

  Lung transplantation can offer meaningful survival and improved quality of life for people with advanced respiratory disease when conventional treatment can no longer control progressive respiratory failure. It is used for carefully selected patients with conditions such as pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary arterial hypertension.

  The decision involves more than measuring lung function. A transplant team evaluates the expected course of the disease, the risk of death without transplantation, functional status, other medical conditions, psychosocial readiness, and the likelihood that the patient can manage lifelong immunosuppression. Timing is critical: referral that occurs too late may leave insufficient time to complete assessment or address reversible problems.

  Current evidence discussed in respiratory medicine forums, including congresses connected with APSR and KATRD, emphasizes individualized selection and long-term follow-up. Advances in donor management, surgical technique, infection prevention, and immunosuppressive therapy have improved outcomes, although transplantation remains a demanding treatment with substantial risks.

  When Referral Should Begin

  Referral generally becomes appropriate when a chronic lung condition is progressive despite optimized therapy, when life expectancy is limited, or when daily function and quality of life have deteriorated substantially. A falling forced vital capacity in pulmonary fibrosis, frequent exacerbations in COPD or cystic fibrosis, increasing oxygen requirements, pulmonary hypertension, or repeated hospital admissions may all prompt specialist review.

  Referral is different from active listing. Early assessment gives clinicians time to improve nutrition, physical conditioning, vaccination status, and control of infection. It also allows evaluation of kidney, liver, cardiac, and vascular health before the patient becomes critically ill. For some diseases, rapid decline can occur after a period of relative stability, making early contact with a transplant center especially important.

  Current Candidate Selection Criteria

  A candidate typically has advanced, irreversible lung disease with a high predicted risk of death over the next one to two years and no equally effective alternative treatment. The person should also have a reasonable chance of surviving the operation and benefiting from a functioning graft. Age is considered alongside frailty and biological fitness rather than used as an isolated cutoff.

  Assessment includes pulmonary function tests, exercise capacity, imaging, blood gases, cardiac evaluation, infection screening, cancer screening, and laboratory testing. Teams also review previous operations, medication adherence, substance use, social support, and the ability to attend frequent appointments. Severe frailty, untreated malignancy, uncontrolled infection, active smoking, and major irreversible organ failure can prevent listing or require correction before transplantation.

  Choosing The Transplant Approach

  A single-lung transplant may be suitable for selected patients with emphysema or some forms of pulmonary fibrosis. It can involve a shorter operation and may use donor organs more efficiently. However, the remaining native lung can continue to cause problems, particularly when infection, severe hyperinflation, or disease-related pulmonary hypertension is present.

  Bilateral transplantation is often preferred for cystic fibrosis, bronchiectasis, severe pulmonary hypertension, and many patients with advanced interstitial lung disease. It may provide better overall respiratory reserve, although the procedure is more extensive. The final choice depends on diagnosis, age, anatomy, blood group, donor availability, center experience, and the patient’s clinical urgency.

  Early Recovery And Long-Term Outcomes

  After surgery, early risks include primary graft dysfunction, bleeding, airway complications, acute rejection, kidney injury, and bacterial, viral, or fungal infection. Intensive rehabilitation, nutritional support, careful fluid management, and early mobilization are central to recovery. Immunosuppressive treatment commonly combines a calcineurin inhibitor, an antiproliferative agent, and corticosteroids.

  Long-term survival varies by diagnosis, transplant type, age, comorbidities, donor characteristics, and complications. Contemporary registry data suggest that bilateral recipients often achieve longer median survival than single-lung recipients, while individual results differ considerably. The figures below are broad estimates rather than predictions for a specific patient.

  Outcome measure	Single-lung transplant	Bilateral-lung transplant
  Typical median survival in contemporary series	About 5–6 years	About 7–8 years
  Five-year survival	Approximately 45–55%	Approximately 55–65%
  Common long-term limitation	Native-lung disease or graft dysfunction	Chronic lung allograft dysfunction
  Main ongoing requirements	Immunosuppression and surveillance	Immunosuppression and surveillance

  Chronic lung allograft dysfunction, often abbreviated CLAD, is the leading long-term barrier to durable graft function. It includes patterns such as bronchiolitis obliterans syndrome and restrictive allograft syndrome. A gradual fall in spirometry may be the first warning sign, which is why scheduled pulmonary function testing remains essential even when symptoms are mild.

  Protecting The Transplanted Lungs

  Infection prevention is a lifelong priority. Patients require individualized vaccination, antimicrobial prophylaxis during specified periods, screening for latent infections, and prompt assessment of fever, cough, breathlessness, or declining lung function. Exposure to tobacco smoke and other inhaled pollutants should be avoided completely.

  Immunosuppressive drugs reduce rejection but increase susceptibility to infection, kidney disease, hypertension, diabetes, osteoporosis, and certain cancers. Regular blood tests help clinicians adjust drug levels and detect organ toxicity. Bronchoscopy, imaging, spirometry, and sometimes donor-specific antibody testing support surveillance for rejection and graft injury.

  Priorities For Better Patient Selection

  Transplant programs can improve outcomes by combining objective measurements with repeated clinical assessment rather than relying on a single test. Practical priorities include:

  • Refer patients before severe deconditioning, malnutrition, or critical illness limits their options.
  • Use diagnosis-specific markers, such as pulmonary fibrosis progression, exacerbation frequency, or pulmonary hypertension severity.
  • Treat reversible risks, including active infection, poor dental health, anemia, and inadequate immunization.
  • Assess frailty, cognition, mental health, adherence, and caregiver support alongside cardiopulmonary data.
  • Maintain shared decision-making about expected survival, quality of life, complications, and the demands of lifelong follow-up.

  Moving From Evaluation To Lifelong Care

  The best transplant pathway begins well before an organ offer. Patients and families need clear information about waiting-list uncertainty, rehabilitation, medication schedules, infection precautions, fertility and pregnancy considerations, travel, employment, and warning signs that require urgent medical attention. Coordinated care between the transplant center and local respiratory team makes this intensive process more manageable.

  Lung transplantation remains a carefully balanced intervention: it can extend life and restore activity, yet it requires continuous monitoring and disciplined self-care. Clinicians should apply current evidence while tailoring decisions to disease trajectory, physiological reserve, donor availability, and patient goals. Specialist referral, structured evaluation, and long-term surveillance are the essential next steps for eligible patients.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)